Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Moderna, Baxter, and Pfizer are our top healthcare picks.

TV personality Tucker Carlson was left stunned during an episode of his podcast when presented with a sobering figure about ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

G avi, the Vaccine Alliance, supplies vaccines to nearly half of the world’s children. For decades, governments, institutions ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field ...